Overview
About UMN Pharma
UMN Pharma Inc. is a pharmaceutical company dedicated to developing innovative pharmaceutical products that will satisfy unmet medical needs; our most important mission is to provide good candidates having proof of concept in clinical stage to big Pharma. Our core competencies reside in utilizing our significant experience in the pharmaceutical industry to generate time-efficient, focused development plans followed by rapid preclinical and clinical development to meet international regulatory specifications. We have a pipeline of diverse novel small molecule and protein drug candidates targeting large (cancer and diabetes) and relatively small (pancreatitis and muscular dystrophy) pharmaceutical markets that are seriously underserved by existing therapeutics, and influenza vaccine.
We have raised approximately $41.8 million from 25 prominent investors including Pacific Rim Ventures, Nomura Research & Advisory, NIF SMBC Ventures ASTEC IHI IPEC and API.
Company Data
| Company Name | UMN Pharma Inc. |
|---|---|
| Incorporated | April 20, 2004 |
| President | Shuichi Kanazashi, M.D.,Ph.D. |
| Akita office | 901, 3-1-9, Nakadori, Akita-city, Akita 010-0001, Japan TEL +81-18-884-0577 FAX +81-18-884-0578 |
| Yokohama head office | NOF Shin-yokohama Bldg. 4th Floor, 2-15-16, Shin-yokohama, Kohoku-ku, Yokohama-city, Kanagawa 222-0033, Japan TEL +81-45-624-8341 FAX +81-45-624-8342 |
| US liaison | Jonathan M. Drutz 101 Oak Tree Drive, Chapel Hill, NC 27517, USA |
| Akita labo. | Molecular Medicine Laboratory, Bioscience Education and Research Center, Akita University, 1-1-1, Hondo, Akita, Akita 010-8543, Japan TEL +81-18-884-6280 FAX +81-18-884-6280 |